Community Clinical · ·
项目来源
项目主持人
项目受资助机构
立项年度
立项时间
项目编号
研究期限
项目级别
受资助金额
学科
学科代码
基金类别
关键词
参与者
参与机构
1.Ra···mi··· p···e ···st··· o···wo···in···ca···ch···le···or···ti···s ···h ···as···ic···ea···ca···r ···ra···ry··· a···nt···cy···ne··· t···ne···r ···h
- 关键词:
- PHARMACOKINETIC TRIAL; FLUOROURACIL FAILURE; VINORELBINE; CAPECITABINE;MULTICENTER; PACLITAXEL; INFUSION; CPT-11; CAMPTOTHECIN; GEMCITABINE
- Pe···, ···Hi···an···W;···ll···d,···;I···e,···;R···, ···Fi···, ···Ro···nd···M;···di···, ···Kr···, ···Ku···r,···;D···il···R
- 《39···An···l ···ti···of···e ···ri···-S···et···f-···ni···-O···lo···》
- 2004年
- MAY 31-JUN 03, 2003
- Ch···go···L
- 会议
Pu···se···pr···in···ee···xi··· f···ag···s ···iv···ga···t ···hr···cl···- ···ta···e-···ra···ry···ta···ti···re··· c···er···BC···or···th···re···us···in···l ···al···ug···te···ha···ri···ec···mi··· h··· s··· a···vi··· W···on···te···hi···ul···en··· p···e ···st··· t···ss··· e···ca···an···ol···bi···y ···tw···ri···ec···sc···ul···Pa···nt···nd···th··· M···pa···nt···ho···pe···nc···di···se···og···si···af··· o···to···re···he···he···y ···im···, ···lu···g ···le··· o···an···ac···in···or···xa···ba··· r···me···we···ra···ml···ss···ed··· i···ot···n ···6-···k ···le···om···si···10···g/···) ···kl···or···we···, ···n ···-w··· r··· (···kl···or···0 ···m(···ev··· 3···ek···es···s ··· w···ly···m ··· 5···ss···ab···pa···nt···th···ve···3-···ks···m ··· 5···ss···ab···pa···nt···In···e ···kl···rm···he···je···ve···sp···e ···mp···e ···re···on···R]···pa···al···gr···io···PR···ra···wa···3%···ne···, ···PR···5%···, ··· t···7%···Me···n ···po··· d···ti···wa···.9···nt···(r···e,···9 ···15···mo···s)···nd···di···ov···ll···rv···l ··· 9···mo···s ···% ··· 8···to···.2···nt···. ···th···ve···3-···ks···m,···e ···ec···e ···po··· r··· w···14···ni···PR···5%···, ···to···%)···ed··· r···on···du···io···as···2 ···th···ra···, ··· t···3.···on···),···d ···ia···ve···l ···vi··· w···8.···on··· (··· C···7.···o ···3 ···th··· T···tm··· g···ra··· w···we···to···at··· e···ci···y ···th···ee··· a··· G···e ···o ···dv···e ···nt···it···re···r ···n ···eq··· t···0%···ci···ce···cl···d ···tr···ni···29···an···ia···ea···7%···n ··· w···ly···m ··· n···ro···ia···6%···vo···in···20··· d···ne···18··· n···ea···6%···an···ia···ea···2%···n ··· e···y-···ee···ar···on···si···Ir···te··· i···ct··· w··· g··· t···ra···it···n ···ra···ry···C.···in···ca···es···ia··· w···ly···ar···ts···di···na···tu···as···no···ra···an···n ···bi···io···eg···ns··· t··· s···in···(C···00···y ···ri··· S···et···f ···ni··· O···lo···
...
